Patients with a history of any arterial thrombotic event within the past  months; this includes angina (stable or unstable), myocardial infarction (MI), transient ischemic attack (TIA), or cerebrovascular accident (CVA)
Significant thromboembolic or vascular disorders within  months prior to administration of first dose of study drug, including but not limited to:\r\n* Deep vein thrombosis\r\n* Pulmonary embolism\r\n* Cerebrovascular accident (CVA) or transient ischemic attack (TIA)\r\n* Peripheral arterial ischemia > grade  (per National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version .)
History of arterial thrombotic disease, specifically including, but not restricted to: \r\n* Myocardial infarction or unstable angina\r\n* Cerebrovascular event (CVA) or transient ischemic attack (TIA)\r\n* Peripheral vascular disease or claudication
No arterial thrombotic events within  months of registration, including transient ischemic attack (TIA), cerebrovascular accident (CVA), peripheral arterial thrombus, unstable angina or angina requiring surgical or medical intervention in the past  months, or myocardial infarction (MI); patients with clinically significant peripheral artery disease (i.e., claudication on less than one block) are ineligible \r\n* Patients who have experienced a deep venous thrombosis or pulmonary embolus within the past  months must be on stable therapeutic anticoagulation to be enrolled to this study
Any of the following within  months before the enrollment:\r\n* Unstable angina pectoris;\r\n* Clinically-significant cardiac arrhythmias;\r\n* Stroke (including transient ischemic attack [TIA], or other ischemic event);\r\n* Myocardial infarction;\r\n* Thromboembolic event requiring therapeutic anticoagulation (Note: subjects with a venous filter [eg, vena cava filter] are not eligible for this study)
Absence of the following in the previous  months:\r\n* Myocardial infarction;\r\n* Unstable angina pectoris;\r\n* Clinically-significant cardiac arrhythmias;\r\n* Stroke (including transient ischemic attack [TIA], or other ischemic event);\r\n* Thromboembolic event requiring therapeutic anticoagulation (Note: subjects with a venous filter [eg, vena cava filter] are not eligible for this study)
Any of the following within  months before the first dose of study treatment:\r\n* Unstable angina pectoris\r\n* Clinically-significant cardiac arrhythmias\r\n* Stroke (including transient ischemic attack [TIA], or other ischemic event)\r\n* Myocardial infarction\r\n* Thromboembolic event requiring therapeutic anticoagulation (Note: subjects with a venous filter [e.g. vena cava filter] are not eligible for this study)
Significant arterial or venous thromboembolic disease or vascular disorders within  months prior to administration of first dose of study drug, including by not limited to:\r\n* Cerebrovascular accident (CVA) or transient ischemic attack (TIA)\r\n* Peripheral ischemia > grade  (per Common Terminology Criteria for Adverse Events [CTCAE] version .)\r\n* Arterial thrombotic event
Any history of myocardial infarction (MI), unstable angina, cerebrovascular accident, or Transient Ischemic Attack (TIA)
Patients with stroke or transient ischemic attack (TIA) within  days prior to enrollment; or peripheral vascular disease requiring intervention within the  days prior to enrollment; or any known hemodynamically significant lesion or embolic plaque
Has a history of an arterial thromboembolic event within the prior six months including CVA, TIA, MI, or unstable angina
Patients with any history of arterial thromboembolic disease; any patient with a history of myocardial infarction (MI), stroke, transient ischemic attack (TIA), unstable angina or peripheral vascular disease will not be eligible
Patients with a history of embolic events (e.g. TIA) from arrhythmia or peripheral arterial disease or of recent MI whether or not treated with anti-platelet drugs
Arterial thromboembolic events, including transient ischemic attack (TIA), cerebrovascular accident (CVA), unstable angina, or MI within  months of study registration
No history of acute arterial thrombotic events within the past  months (including cerebrovascular accident [CVA], transient ischemic attack [TIA], myocardial infarction [MI], or unstable angina)
No clinically significant cardiovascular disease\r\n* Patients with a history of hypertension must be well controlled (< /) on a regimen of antihypertensive therapy\r\n* History of arterial thrombotic events within the past  months, including transient ischemic attack (TIA), cerebrovascular accident (CVA), peripheral arterial thrombus, unstable angina, or angina requiring surgical or medial intervention in the past  months, or myocardial infarction (MI); patients with clinically significant peripheral artery disease (i.e., claudication on less than one block), significant vascular disease (i.e., aortic aneurysm, history of aortic dissection) are not eligible\r\n* Patients who have had a deep vein thrombosis or pulmonary embolus within the past  months are eligible if they are on stable therapeutic anticoagulation\r\n* No current New York Heart Association classification II, III, or IV congestive heart failure
Arterial thrombotic events =<  months prior to randomization; Note: this includes transient ischemic attack (TIA), cerebrovascular accident (CVA), unstable angina or angina requiring surgical or medical intervention in the past  months, or myocardial infarction (MI)
Significant thromboembolic or vascular disorders within  months prior to administration of first dose of study drug, including but not limited to:\r\n* Deep vein thrombosis\r\n* Pulmonary embolism\r\n* Cerebrovascular accident (CVA) or transient ischemic attack (TIA)\r\n* Peripheral arterial ischemia > grade  (per National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version .)
No arterial thrombotic events within  months of registration, including transient ischemic attack (TIA), cerebrovascular accident (CVA), peripheral arterial thrombus, myocardial infarction (MI), or unstable angina or angina requiring surgical or medical intervention in  months prior to registration; patients with clinically significant peripheral artery disease (i.e., claudication on less than one block) are ineligible; patients who have experienced a deep venous thrombosis or pulmonary embolus within  months prior to registration must be on stable therapeutic anticoagulation for at least  weeks prior to enrollment of this study
History of arterial/myocardial disease
History of an arterial thrombotic vascular event including cerebrovascular accident (CVA), myocardial infarction (MI), unstable angina, coronary or peripheral arterial bypass graft, or transient ischemic attack (TIA) within  months
History of arterial thrombotic events within  months before randomization, including transient ischemic attack (TIA), cerebrovascular accident (CVA), unstable angina or angina requiring surgical or medical intervention in the past  months, or myocardial infarction (MI); patients with clinically significant peripheral artery disease (e.g., claudication with <  block) or any other arterial thrombotic event are also ineligible
Patients with a history of embolic events (e.g. transient ischemic attack [TIA]) from arrhythmia or peripheral arterial disease or of recent myocardial infarction (MI) whether or not treated with anti-platelet drugs
Any of the following within the  months prior to study drug administration: myocardial infarction, grade  or greater peripheral vascular disease, arterial thrombotic event, visceral arterial ischemia, cerebrovascular ischemia, transient ischemic attack, percutaneous transluminal angioplasty or stent, or unstable angina
The subject has the following cardiac conditions: unstable angina pectoris, clinically significant cardiac arrhythmias, history of stroke (including transient ischemic attack [TIA], or other ischemic event) within  months of study treatment, myocardial infarction within  months of study treatment, history of thromboembolic event requiring therapeutic anticoagulation within  months of study treatment or main portal vein or vena cava thrombosis or occlusion; (Note: subjects with a venous filter [e.g. vena cava filter] are not eligible for this study)
No history of arterial thrombotic events within the past  months, including:\r\n* Transient ischemic attack (TIA)\r\n* Cerebrovascular accident (CVA)\r\n* Peripheral arterial thrombus\r\n* Unstable angina or angina requiring surgical or medial intervention\r\n* Myocardial infarction (MI)\r\n* Significant peripheral artery disease (i.e., claudication on less than one block)\r\n* Significant vascular disease (i.e., aortic aneurysm, history of aortic dissection)
Any contraindications to vigorous exercise, including, but not limited to: brain metastases; current congestive heart failure (New York Heart Association class II, III or IV); serious or non-healing wound, ulcer, or bone fracture; spinal cord compromise or instrumentation due to metastatic disease; peripheral neuropathy >= grade ; no serious cardiovascular events within  months including, but not limited to, transient ischemic attack (TIA), cerebrovascular accident (CVA), or myocardial infarction (MI)
Atherosclerotic cardiovascular disease (ASCVD) defined by history of acute coronary syndromes, myocardial infarction (MI), stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemic attack (TIA), or peripheral arterial disease presumed to be of atherosclerotic origin
Clinical history of cardiovascular disease (CVD) occurring within the past  months, including myocardial infarction, angina, coronary revascularization, stroke, transient ischemic attack (TIA), carotid revascularization, peripheral arterial disease, and congestive heart failure
